You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
步長製藥(603858.SH):控股子公司浙江天元與蘭州百靈簽訂產品研發合作協議
格隆匯 06-01 18:29

格隆匯6月1日丨步長製藥(603858.SH)公佈,近日,山東步長製藥股份有限公司(以下簡稱“公司”)控股子公司浙江天元生物藥業有限公司(以下簡稱“浙江天元”)與蘭州百靈生物技術有限公司(以下簡稱“蘭州百靈”)簽訂《產品研發合作協議》及相關補充協議,蘭州百靈將四價流感病毒裂解疫苗產品己有研發技術有償轉讓給浙江天元,雙方基於蘭州百靈現有的研究基礎,進一步共同設計和研發四價流感病毒裂解疫苗產品;同時,浙江天元與西北民族大學簽訂《技術服務協議》及相關補充協議,西北民族大學為浙江天元提供四價流感病毒裂解疫苗產品研發的技術服務,包括生產用細胞庫的建立,細胞生長特性、遺傳特性、外源物污染、成瘤性和致瘤性檢定,細胞生物反應器片狀載體培養和全懸浮培養技術,人員培訓等技術與服務,助力浙江天元產品研發。

本次浙江天元與第三方簽訂上述合同,有利於擴大公司藥品研發能力和範圍,節約公司研發成本,分攤研發風險,一定程度上節約了公司藥品臨牀試驗的時間和成本,保障項目的順利進行。本次《產品研發合作協議》、《技術服務協議》及相關補充協議的金額不會對公司及控股子公司財務狀況和經營成果產生不利影響,且合同均以上述藥品獲准上市為目標,將對公司產生積極影響。

由於醫藥產品具有高科技、高風險、高附加值的特點,產品從研製、臨牀試驗報批到投產的週期長、環節多,容易受到一些不確定性因素的影響。敬請廣大投資者謹慎決策,注意防範投資風險。公司將按有關規定,及時履行對項目後續進展情況信息披露義務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account